Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial
Why the study?
Is 6-week treatment with sibutramine efficacious, tolerable, and safe in high-risk subjects for whom it is usually contraindicated?
Population
High-risk subjects for whom sibutramine is usually contraindicated
Design
Other
Follow-up
6 weeks
Authors
Discussion
Loading...
Member takes
Implication
Supports short-term use despite contraindications in high-risk patients; challenges labeling and extends RCT safety data.
Structured PICO
Is 6-week treatment with sibutramine efficacious, tolerable, and safe in high-risk subjects for whom it is usually contraindicated?
P
Population
High-risk subjects for whom sibutramine is usually contraindicated
I
Intervention
Sibutramine (6-week treatment)
O
Outcome
Efficacy, tolerability, and safetysafety
Six-week treatment with sibutramine appears safe and tolerable in high-risk subjects where it is typically contraindicated.
Cite This Study
Torp‐Pedersen et al. (2007) studied this question.